Trial reportJournal of diabetes science and technology2018
The Comprehensive Glucose Pentagon: A Glucose-Centric Composite Metric for Assessing Glycemic Control in Persons With Diabetes.
Trial report in Journal of diabetes science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Hybrid Closed-Loop Versus Manual Insulin Delivery in Adults With Type 1 Diabetes: A Post Hoc Analysis Using the Glycemia Risk Index.Journal of diabetes science and technology · 2024Trial
- The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review.JMIR diabetes · 2026Review
- Glucose360: An Open-Source Python Platform with Event-Based Integration for Continuous Glucose Monitoring Data Analysis.Diabetes technology & therapeutics · 2026Article
- Short-term Glycemic Variability and Its Association With Macrovascular and Microvascular Complications in Patients With Diabetes.Journal of diabetes science and technology · 2024Review
- Patient-Tailored Decision Support System Improves Short- and Long-Term Glycemic Control in Type 2 Diabetes.Journal of diabetes science and technology · 2022Observational
- Circulating osteocalcin is associated with time in range and other metrics assessed by continuous glucose monitoring in type 2 diabetes.Diabetology & metabolic syndrome · 2022Article
- Glycaemic Variability and Risk Factors of Pregnant Women with and without Gestational Diabetes Mellitus Measured by Continuous Glucose Monitoring.International journal of environmental research and public health · 2021Article
- Glycemic deviation index: a novel method of integrating glycemic numerical value and variability.BMC endocrine disorders · 2021Article
- Spousal Influence on Diabetes Self-care: Moderating Effects of Distress and Relationship Quality on Glycemic Control.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2021Observational
- Glycemic Status Assessment by the Latest Glucose Monitoring Technologies.International journal of molecular sciences · 2020Review
- A Review of Continuous Glucose Monitoring-Based Composite Metrics for Glycemic Control.Diabetes technology & therapeutics · 2020Review
- Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.Journal of diabetes science and technology · 2020Article
- Positioning time in range in diabetes management.Diabetologia · 2020Review
- Time in range: a new parameter to evaluate blood glucose control in patients with diabetes.Diabetology & metabolic syndrome · 2020Review
- How Knowledge Emerges From Artificial Intelligence Algorithm and Data Visualization for Diabetes Management.Journal of diabetes science and technology · 2019Article
- Spousal Involvement in Collaborative Management and Glycemic Behavior Change among Patients with Diabetes Mellitus: A Systematic Review.SAGE open nursingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComposite metrics have the potential to provide more complete and clinically useful information about glycemic control than traditional individual metrics such as hemoglobin A1C, %/time/area under curve of hypoglycemia and hyperglycemia.
methodsUsing five key metrics that are derived from continuous glucose monitoring, we developed a new, multicomponent composite metric, the Comprehensive Glucose Pentagon (CGP) that demonstrates glycemic control both numerically and visually. Two of its axes are composite metrics-the intensity of hypoglycemia and intensity of hyperglycemia. This approach eliminates the use of the surrogate marker, hemoglobin A1C (A1C), and replaces it with glucose-centric metrics.
resultsWe reanalyzed the data from two randomized control trials, the STAR 3 and ASPIRE In-Home studies using the CGP. It provided new insights into the effect of sensor-augmented pumping (SAP) in the STAR 3 trial and sensor-integrated pumping with low-glucose threshold suspend (SIP+TS) in the ASPIRE In-Home trial.
conclusionsThe CGP has the potential to enable health care providers, investigators and patients to better understand the components of glycemic control and the effect of various interventions on the individual elements of that control. This can be done on a daily, weekly, or monthly basis. It also allows direct comparison of the effects on different interventions among clinical trials which is not possible using A1C alone. This new composite metric approach requires validation to determine if it provides a better predictor of long-term outcomes than A1C and/or better predictor of severe hypoglycemia than the low blood glucose index (LBGI).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.